STOCK TITAN

[Form 4] Orthofix Medical Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Orthofix Medical (OFIX) filed a Form 4 disclosing that director Charles R. Kummeth was granted 18,841 deferred stock units (DSUs) on 06/18/2025 at no cost. The DSUs vest in full on the first anniversary of the grant date and will convert into common stock within 45 days after his service with the company ends. Following the award, Kummeth’s total beneficial ownership rose to 59,237 shares, which now includes 23,502 previously reported DSUs and 1,894 shares accumulated through Orthofix’s Stock Purchase Plan.

Orthofix Medical (OFIX) ha presentato un Modulo 4 comunicando che il direttore Charles R. Kummeth ha ricevuto 18.841 unità azionarie differite (DSU) il 18/06/2025 senza alcun costo. Le DSU maturano completamente al primo anniversario della data di assegnazione e si convertiranno in azioni ordinarie entro 45 giorni dalla fine del suo servizio in azienda. Dopo l’assegnazione, la proprietà beneficiaria totale di Kummeth è salita a 59.237 azioni, che includono ora 23.502 DSU precedentemente segnalate e 1.894 azioni accumulate tramite il Piano di Acquisto Azionario di Orthofix.

Orthofix Medical (OFIX) presentó un Formulario 4 revelando que el director Charles R. Kummeth recibió 18,841 unidades diferidas de acciones (DSUs) el 18/06/2025 sin costo alguno. Las DSUs se consolidan completamente en el primer aniversario de la fecha de concesión y se convertirán en acciones comunes dentro de los 45 días posteriores a la finalización de su servicio con la empresa. Tras la adjudicación, la propiedad beneficiaria total de Kummeth aumentó a 59,237 acciones, que ahora incluyen 23,502 DSUs reportadas anteriormente y 1,894 acciones acumuladas a través del Plan de Compra de Acciones de Orthofix.

Orthofix Medical (OFIX)는 이사 Charles R. Kummeth가 2025년 6월 18일에 비용 없이 18,841개의 이연 주식 단위(DSU)를 부여받았음을 알리는 Form 4를 제출했습니다. DSU는 부여일로부터 1주년이 되는 날 전액 취득되며, 그의 회사 근무가 종료된 후 45일 이내에 보통주로 전환됩니다. 이 수여 이후 Kummeth의 총 실질 소유 주식 수는 59,237주로 증가했으며, 여기에는 이전에 보고된 23,502 DSU와 Orthofix 주식 매입 계획을 통해 누적된 1,894주가 포함됩니다.

Orthofix Medical (OFIX) a déposé un formulaire 4 révélant que le directeur Charles R. Kummeth a reçu 18 841 unités d’actions différées (DSU) le 18/06/2025 sans frais. Les DSU seront entièrement acquises à la date du premier anniversaire de l’attribution et seront converties en actions ordinaires dans les 45 jours suivant la fin de son service au sein de l’entreprise. Suite à cette attribution, la propriété bénéficiaire totale de Kummeth a augmenté pour atteindre 59 237 actions, incluant désormais 23 502 DSU précédemment déclarées et 1 894 actions accumulées via le Plan d’Achat d’Actions d’Orthofix.

Orthofix Medical (OFIX) reichte ein Formular 4 ein, in dem offengelegt wurde, dass der Direktor Charles R. Kummeth am 18.06.2025 18.841 aufgeschobene Aktienanteile (DSUs) ohne Kosten erhalten hat. Die DSUs werden am ersten Jahrestag des Gewährungsdatums vollständig unverfallbar und werden innerhalb von 45 Tagen nach Beendigung seiner Tätigkeit für das Unternehmen in Stammaktien umgewandelt. Nach der Zuteilung stieg Kummeths gesamter wirtschaftlicher Eigentumsanteil auf 59.237 Aktien, die nun 23.502 zuvor gemeldete DSUs und 1.894 Aktien aus dem Aktienkaufplan von Orthofix umfassen.

Positive
  • Material ownership increase: Director Charles R. Kummeth received 18,841 deferred stock units (~46 % addition), lifting his stake to 59,237 shares.
Negative
  • None.

Insights

TL;DR: Director granted 18,841 DSUs—material size but compensation-driven; neutral market signal.

The transaction adds roughly 46 % to Charles Kummeth’s prior stake, surpassing materiality thresholds for insider filings. Because the award is service-based and settled post-tenure, it does not represent immediate cash buying or selling pressure. The filing lacks price data, open-market activity, or derivative exercises, suggesting a neutral impact for near-term trading sentiment while modestly strengthening long-term alignment.

Orthofix Medical (OFIX) ha presentato un Modulo 4 comunicando che il direttore Charles R. Kummeth ha ricevuto 18.841 unità azionarie differite (DSU) il 18/06/2025 senza alcun costo. Le DSU maturano completamente al primo anniversario della data di assegnazione e si convertiranno in azioni ordinarie entro 45 giorni dalla fine del suo servizio in azienda. Dopo l’assegnazione, la proprietà beneficiaria totale di Kummeth è salita a 59.237 azioni, che includono ora 23.502 DSU precedentemente segnalate e 1.894 azioni accumulate tramite il Piano di Acquisto Azionario di Orthofix.

Orthofix Medical (OFIX) presentó un Formulario 4 revelando que el director Charles R. Kummeth recibió 18,841 unidades diferidas de acciones (DSUs) el 18/06/2025 sin costo alguno. Las DSUs se consolidan completamente en el primer aniversario de la fecha de concesión y se convertirán en acciones comunes dentro de los 45 días posteriores a la finalización de su servicio con la empresa. Tras la adjudicación, la propiedad beneficiaria total de Kummeth aumentó a 59,237 acciones, que ahora incluyen 23,502 DSUs reportadas anteriormente y 1,894 acciones acumuladas a través del Plan de Compra de Acciones de Orthofix.

Orthofix Medical (OFIX)는 이사 Charles R. Kummeth가 2025년 6월 18일에 비용 없이 18,841개의 이연 주식 단위(DSU)를 부여받았음을 알리는 Form 4를 제출했습니다. DSU는 부여일로부터 1주년이 되는 날 전액 취득되며, 그의 회사 근무가 종료된 후 45일 이내에 보통주로 전환됩니다. 이 수여 이후 Kummeth의 총 실질 소유 주식 수는 59,237주로 증가했으며, 여기에는 이전에 보고된 23,502 DSU와 Orthofix 주식 매입 계획을 통해 누적된 1,894주가 포함됩니다.

Orthofix Medical (OFIX) a déposé un formulaire 4 révélant que le directeur Charles R. Kummeth a reçu 18 841 unités d’actions différées (DSU) le 18/06/2025 sans frais. Les DSU seront entièrement acquises à la date du premier anniversaire de l’attribution et seront converties en actions ordinaires dans les 45 jours suivant la fin de son service au sein de l’entreprise. Suite à cette attribution, la propriété bénéficiaire totale de Kummeth a augmenté pour atteindre 59 237 actions, incluant désormais 23 502 DSU précédemment déclarées et 1 894 actions accumulées via le Plan d’Achat d’Actions d’Orthofix.

Orthofix Medical (OFIX) reichte ein Formular 4 ein, in dem offengelegt wurde, dass der Direktor Charles R. Kummeth am 18.06.2025 18.841 aufgeschobene Aktienanteile (DSUs) ohne Kosten erhalten hat. Die DSUs werden am ersten Jahrestag des Gewährungsdatums vollständig unverfallbar und werden innerhalb von 45 Tagen nach Beendigung seiner Tätigkeit für das Unternehmen in Stammaktien umgewandelt. Nach der Zuteilung stieg Kummeths gesamter wirtschaftlicher Eigentumsanteil auf 59.237 Aktien, die nun 23.502 zuvor gemeldete DSUs und 1.894 Aktien aus dem Aktienkaufplan von Orthofix umfassen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kummeth Charles R.

(Last) (First) (Middle)
3451 PLANO PARKWAY

(Street)
LEWISVILLE TX 75056

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Orthofix Medical Inc. [ OFIX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/18/2025 A 18,841(1) A $0 59,237(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents an award of deferred stock units that vest in full on the first anniversary of the grant date, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer.
2. Includes 23,502 previously reported deferred stock units and an aggregate of 1,894 shares acquired under Orthofix's Stock Purchase Plan on 10/31/2024 and 4/30/2025..
/s/ Geoffrey Gillespie, attorney-in-fact 06/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many shares did Orthofix (OFIX) director Charles R. Kummeth acquire on 06/18/2025?

The Form 4 reports an award of 18,841 deferred stock units.

What is Charles R. Kummeth’s total beneficial ownership in OFIX after the transaction?

His holdings increased to 59,237 shares of Orthofix common stock.

When do the newly granted deferred stock units vest?

The DSUs vest in full on the first anniversary of the 06/18/2025 grant date, subject to continued service.

Are the shares from this Form 4 an open-market purchase?

No. They are service-based deferred stock units granted at no cash cost.

What other shares are included in Kummeth’s ownership total?

The total includes 23,502 previously reported DSUs and 1,894 shares bought through the company’s Stock Purchase Plan.
Orthofix Med Inc

NASDAQ:OFIX

OFIX Rankings

OFIX Latest News

OFIX Latest SEC Filings

OFIX Stock Data

562.79M
38.53M
2.76%
91.93%
4.6%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
LEWISVILLE